A practical reference on freeze-thaw cycle: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-25 and is reviewed periodically as new material appears.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
=== Atherosclerosis === Rapamycin can accelerate degradation of oxidized LDL cholesterol in endothelial cells, thereby lowering the risk of atherosclerosis. Oxidized LDL cholesterol is a major contributor to atherosclerosis.
=== Army leadership resignations === In April 2026, Hegseth fired Army Chief of Staff Gen. Randy George which has left the longest break without a service chief in Army history and making him one of eight high ranking members of the military fired or forced out by the secretary of defense. On August 31, 2026 Secretary of the Army Dan Driscoll gave Hegseth his resignation after a face to face meeting Driscoll had with President Trump where he stated his concerns over the number of army generals fired under Hegseth.
== Further reading == Edwards, Clive A. (ed.) Earthworm Ecology. Boca Raton: CRC Press, 2004. Second revised edition. ISBN 0-8493-1819-X Lee, Keneth E. Earthworms: Their Ecology and Relationships with Soils and Land Use. Academic Press. Sydney, 1985. ISBN 0-12-440860-5 Stewart, Amy. The Earth Moved: On the Remarkable Achievements of Earthworms. Chapel Hill, N.C.: Algonquin Books, 2004. ISBN 1-56512-337-9
Sources: en.wikipedia.org
=== SB Pharmco Puerto Rico === In 2010, the US Department of Justice announced that GSK would pay a US$150 million criminal fine and forfeiture, and a civil settlement of US$600 million under the False Claims Act. The fines stemmed from production of improperly made and adulterated drugs from 2001 to 2005, at GSK's subsidiary, SB Pharmco Puerto Rico Inc., in Cidra, Puerto Rico, which at the time produced US$5.5 billion of products each year. The drugs involved were Kytril, an antiemetic; Bactroban, used to treat skin infections; Paxil, the anti-depressant; and Avandamet, a diabetes drug. GSK closed the factory in 2009. The case began in 2002, when GSK sent experts to fix problems cited by the FDA. The lead inspector recommended recalls of defective products, but they were not authorised; she was fired in 2003, and filed a whistleblower lawsuit. In 2005, federal marshals seized US$2 billion worth of products, the largest such seizure in history. In the 2010 settlement SB Pharmco pleaded guilty to criminal charges, and agreed to pay US$150 million in a criminal fine and forfeiture, at that time the largest such payment ever by a manufacturer of adulterated drugs, and US$600 million in civil penalties to settle the civil lawsuit.
==== Surface-assisted laser desorption/ionization ==== Surface-assisted laser desorption/ionization (SALDI) is a soft laser desorption technique used for analyzing biomolecules by mass spectrometry. In its first embodiment, it used graphite matrix. At present, laser desorption/ionization methods using other inorganic matrices, such as nanomaterials, are often regarded as SALDI variants. A related method named "ambient SALDI" – which is a combination of conventional SALDI with ambient mass spectrometry incorporating the DART ion source – has also been demonstrated.
=== Pharmacokinetics === The pharmacokinetics of isoergine in rodents have been studied. Isoergine is much less lipophilic than LSD, with log P values of 0.95 and 2.95, respectively. This might influence its pharmacological properties, for instance reducing its blood–brain barrier permeability. However, isoergine showed a similar ratio of brain-to-plasma levels as LSD in rodents.
Sources: en.wikipedia.org
The presence of bulky ligands can also increase the rate of elimination. Ligands such as phosphines with large bite angles cause steric repulsion between L and R1 and R2, resulting in the angle between L and the R groups to increase and the angle between R1 and R2 to hence decrease, allowing for quicker reductive elimination.
In nuclear science a decay chain refers to the predictable series of radioactive disintegrations undergone by the nuclei of certain unstable chemical elements. Radioactive isotopes do not usually decay directly to stable isotopes, but rather into another radioisotope. The isotope produced by this radioactive emission then decays into another, often radioactive isotope. This chain of decays always terminates in a stable isotope, whose nucleus no longer has the surplus of energy necessary to produce another emission of radiation. Such stable isotopes are then said to have reached their ground states. The stages or steps in a decay chain are referred to by their relationship to previous or subsequent stages. Hence, a parent isotope is one that undergoes decay to form a daughter isotope. For example element 92, uranium, has an isotope with 144 neutrons (236U) and it decays into an isotope of element 90, thorium, with 142 neutrons (232Th). The daughter isotope may be stable or it may itself decay to form another daughter isotope. 232Th does this when it decays into radium-228. The daughter of a daughter isotope, such as 228Ra, is sometimes called a granddaughter isotope. 228Ra in turn undergoes a further eight decays and transmutations until a stable isotope, 208Pb, is produced, terminating the decay chain of 236U. The time required for an atom of a parent isotope to decay into its daughter is fundamentally unpredictable and varies widely. For individual nuclei the process is not known to have determinable causes and the time at which it occurs is therefore completely random.
==== Role in cardiac hypertrophy and fibrosis ==== Intracrine Ang II has been implicated in the development of cardiac hypertrophy, a process characterized by the enlargement of cardiac myocytes in response to increased workload or stress. Experimental models have shown that overexpression of non-secreted Ang II in cardiac cells leads to rapid hypertrophy independent of extracellular Ang II signaling. This suggests that intracellular Ang II plays a direct role in cardiomyocyte growth and structural remodeling. Similarly, intracrine Ang II contributes to myocardial fibrosis by upregulating profibrotic cytokines and growth factors, such as transforming growth factor-beta (TGF-β) and platelet-derived growth factor (PDGF). This promotes the excessive deposition of extracellular matrix proteins, leading to stiffening of the cardiac tissue and impaired cardiac function.
=== Secretariat === The commission is serviced by a Secretariat headed by a Secretary with four Additional Secretaries, several Joint Secretaries, Deputy Secretaries, and other supporting staff. The secretariat, for administrative purposes, is further divided into divisions, each undertaking having a specific responsibility:
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.